Neural stem cells for disease modeling and evaluation of therapeutics for infantile (CLN1/PPT1) and late infantile (CLN2/TPP1) neuronal ceroid lipofuscinoses

Ni Sima,
Rong Li,
Wei Huang,
Miao Xu,
Jeanette Beers,
Jizhong Zou,
Steven Titus,
Elizabeth A. Ottinger,
Juan J. Marugan,
Xing Xie and
Wei ZhengEmail author View ORCID ID profile

Orphanet Journal of Rare Diseases201813:54

https://doi.org/10.1186/s13023-018-0798-2

Received: 20 November 2017

Accepted: 29 March 2018

Published: 10 April 2018

Abstract

Background

Infantile and late infantile neuronal ceroid lipofuscinoses (NCLs) are lysosomal storage diseases affecting the central nervous system (CNS). The infantile NCL (INCL) is caused by mutations in the PPT1 gene and late-infantile NCL (LINCL) is due to mutations in the TPP1 gene. Deficiency in PPT1 or TPP1 enzyme function results in lysosomal accumulation of pathological lipofuscin-like material in the patient cells. There is currently no small-molecular drug treatment for NCLs.

Results

We have generated induced pluripotent stem cells (iPSC) from three patient dermal fibroblast lines and further differentiated them into neural stem cells (NSCs). Using these new disease models, we evaluated the effect of δ-tocopherol (DT) and hydroxypropyl-β-cyclodextrin (HPBCD) with the enzyme replacement therapy as the control. Treatment with the relevant recombinant enzyme or DT significantly ameliorated the lipid accumulation and lysosomal enlargement in the disease cells. A combination therapy of δ-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.

Conclusion

The results demonstrate that these patient iPSC derived NCL NSCs are valid cell- based disease models with characteristic disease phenotypes that can be used for study of disease pathophysiology and drug development.

Keywords

Neuronal ceroid lipofuscinosisINCLLINCLLysosomal storage diseaseInduced pluripotent stem cellsNeural stem cellsEnzyme replacement therapyCyclodextrinδ-tocopherol